Literature DB >> 16319613

Drug delivery to the cochlea using PLGA nanoparticles.

Tetsuya Tamura1, Tomoko Kita, Takayuki Nakagawa, Tsuyoshi Endo, Tae-Soo Kim, Tsutomu Ishihara, Yutaka Mizushima, Megumu Higaki, Juichi Ito.   

Abstract

OBJECTIVES: This study aimed to investigate the efficacy of encapsulating therapeutic molecules in poly lactic/glycolic acid (PLGA) nanoparticles for drug delivery to the cochlea. STUDY
DESIGN: An experimental study.
METHODS: We examined the distribution of rhodamine, a fluorescent dye, in the cochlea, liver, and kidney of guinea pigs. Intravenous injection of rhodamine or rhodamine-encapsulated PLGA nanoparticles was used to target the fluorescent dye systemically to the liver, kidney, and cochlea, and these molecules were applied locally to the round window membrane (RWM) of the cochlea. The localization of rhodamine fluorescence in each region was quantitatively analyzed.
RESULTS: After systemic application of rhodamine nanoparticles, fluorescence was identified in the liver, kidney, and cochlea. The systemic application of nanoparticles had a significant effect on targeted and sustained delivery of rhodamine to the liver but not the kidney or cochlea. Rhodamine nanoparticles placed on the RWM were identified in the scala tympani as nanoparticles, indicating that the PLGA nanoparticles can permeate through the RWM. Furthermore, the local application of rhodamine nanoparticles to the RWM was more effective in targeted delivery to the cochlea than systemic application.
CONCLUSIONS: These findings indicate that PLGA nanoparticles can be an useful drug carrier to the cochlea via local application.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319613     DOI: 10.1097/01.mlg.0000180174.81036.5a

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  38 in total

1.  The design and screening of drugs to prevent acquired sensorineural hearing loss.

Authors:  Debashree Mukherjea; Leonard P Rybak; Kelly E Sheehan; Tejbeer Kaur; Vickram Ramkumar; Sarvesh Jajoo; Sandeep Sheth
Journal:  Expert Opin Drug Discov       Date:  2011-03-15       Impact factor: 6.098

Review 2.  [Gene therapy and stem cells for the inner ear: a review].

Authors:  H A Breinbauer; M Praetorius
Journal:  HNO       Date:  2014-02       Impact factor: 1.284

3.  Simulation of application strategies for local drug delivery to the inner ear.

Authors:  Stefan K Plontke; Alec N Salt
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2006-10-26       Impact factor: 1.538

Review 4.  Principles of local drug delivery to the inner ear.

Authors:  Alec N Salt; Stefan K Plontke
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

Review 5.  Current status and prospects of gene therapy for the inner ear.

Authors:  Hong Sun; Aji Huang; Shousong Cao
Journal:  Hum Gene Ther       Date:  2011-05-19       Impact factor: 5.695

Review 6.  Innovative pharmaceutical approaches for the management of inner ear disorders.

Authors:  Umberto M Musazzi; Silvia Franzé; Francesco Cilurzo
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

Review 7.  Intracochlear drug delivery systems.

Authors:  Jeffrey T Borenstein
Journal:  Expert Opin Drug Deliv       Date:  2011-05-26       Impact factor: 6.648

8.  A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application.

Authors:  Shayanne A Lajud; Danish A Nagda; Peter Qiao; Nobuaki Tanaka; Alyssa Civantos; Rende Gu; Zhiliang Cheng; Andrew Tsourkas; Bert W O'Malley; Daqing Li
Journal:  Otol Neurotol       Date:  2015-02       Impact factor: 2.311

Review 9.  Drug delivery for treatment of inner ear disease: current state of knowledge.

Authors:  Andrew A McCall; Erin E Leary Swan; Jeffrey T Borenstein; William F Sewell; Sharon G Kujawa; Michael J McKenna
Journal:  Ear Hear       Date:  2010-04       Impact factor: 3.570

Review 10.  Gene therapy for deafness.

Authors:  D C Kohrman; Y Raphael
Journal:  Gene Ther       Date:  2013-07-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.